YL217 / MediLink - LARVOL DELTA

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

Yilian Biopharmaceuticals' YL217 project completes first patient dosing [Google translation] (Yilian Biopharma Press Release) - "Suzhou Yilian Biopharmaceutical Co., Ltd...announced that its independently developed antibody-drug conjugate YL217 successfully completed the first dosing of the first subject in the global Phase I clinical trial in China."

Trial status • Oncology • Solid Tumor

Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors (AACR 2025) - "Moreover, acceptable safety profiles were also noted in monkey GLP toxicity studies. Taken together, preclinical data suggest that YL217 could be further developed in the treatment of CDH17-positive cancer patients."

Preclinical • Oncology • Solid Tumor • CDH17

A First-in-Human Study of YL217 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=220 | Not yet recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Yilian Biopharmaceuticals’ YL217 project received FDA approval for clinical trials [Google translation] (Yilian Biotech Press Release) - "Suzhou Yilian Biopharmaceutical Co., Ltd...announced that its independently developed antibody-drug conjugate YL217 has obtained implicit approval of the new drug clinical trial application (IND) from the U.S. Food and Drug Administration (FDA)."

IND • Oncology